ASH 2019   |  December 10, 2019   CC-93269 Demonstrates Promising Dose-Dependent Efficacy in Heavily Pretreated Myeloma CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma. Read more   ADVERTISEMENT   Promising Responses from Dual-Targeting CAR T-Cell Therapy in Myeloma Support Further Exploration Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow. Read more